|
|
|
Volumn 23, Issue 5 SUPPL. 10, 1996, Pages 82-89
|
|
An estimate of the cost effectiveness of gemcitabine in stage IV non- small cell lung cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CISPLATIN;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
GEMCITABINE;
NUCLEOSIDE ANALOG;
VINDESINE;
ANTINEOPLASTIC ACTIVITY;
BRONCHOSCOPY;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
FOLLOW UP;
HEALTH CARE COST;
HOSPITALIZATION;
HUMAN;
LUNG BIOPSY;
LUNG NON SMALL CELL CANCER;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
SPUTUM CYTODIAGNOSIS;
THORAX RADIOGRAPHY;
ANTIMETABOLITES, ANTINEOPLASTIC;
CARCINOMA, NON-SMALL-CELL LUNG;
COST-BENEFIT ANALYSIS;
DEOXYCYTIDINE;
HEALTH CARE COSTS;
HUMANS;
LUNG NEOPLASMS;
NEOPLASM STAGING;
|
|
EID: 0029852131
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (26)
|
|
References (0)
|
